Cite
HARVARD Citation
Kar, B. et al. (2022). Iridium(iii)–Cp*-(imidazo[4, 5-f][1, 10]phenanthrolin-2-yl)phenol analogues as hypoxia active, GSH-resistant cancer cytoselective and mitochondria-targeting cancer stem cell therapeutic agents. Dalton transactions. 51 (14), pp. 5494-5514. [Online].